Spatial epidemiological analysis based on township scale and analysis of influencing factors of pulmonary tuberculosis cure of Changshu city from 2015 to 2022.

Publication date: Jan 17, 2025

This study aimed to enhance the prevention and control of pulmonary tuberculosis (PTB) and provide more effective and accurate methods in Changshu City. The PTB patients’ information came from the China Information System for Disease Control and Prevention (CISDCP). The demographic data for Changshu city and towns came from the Suzhou Statistical Yearbook and the LandScan platform. ArcGIS was used for global spatial autocorrelation analysis and local spatial autocorrelation analysis. Univariate logistic regression and multivariate logistic regression were used to analyze the influencing factors of cured PTB patients. The receiver operating characteristic (ROC) curve and decision curve analysis (DCA) were used to analyze the predictive efficacy and clinical benefit of the indicators. XGBoost analysis was performed to explore the feature importance of key metrics for PTB outcome. A total of 3943 PTB cases were included. The annual incidence rate of new PTB in Changshu city was 27. 081 per 100,000. Changshu High-tech Industrial Development Zone in Jiangsu Province and Shajiabang town were the high-high aggregation areas and hot spot areas. Diagnosis delay, TB strain types, and drug sensitivity were independent predictors of the cure of new PTB patients. The central and southern areas of Changshu were the high-high cluster areas and hot spots for PTB. Shorter diagnosis delay days and mycobacterium tuberculosis (MTB) promote the cure of tuberculosis, while drug sensitivity was a risk factor for its cure.

Open Access PDF

Concepts Keywords
China Adolescent
Epidemiological Adult
Mycobacterium Aged
Yearbook China
Cities
Female
Humans
Incidence
Logistic Models
Male
Middle Aged
Mycobacterium tuberculosis
Risk Factors
ROC Curve
Spatial Analysis
Tuberculosis, Pulmonary
Young Adult

Semantics

Type Source Name
disease MESH pulmonary tuberculosis
drug DRUGBANK Saquinavir
drug DRUGBANK Dichloroacetic Acid
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Coenzyme M
drug DRUGBANK Methionine
pathway REACTOME Reproduction
disease MESH infection
disease MESH death
disease MESH infectious diseases
disease MESH non communicable diseases
disease MESH marital status
drug DRUGBANK Ethanol
disease IDO symptom
disease MESH AIDS
drug DRUGBANK Etoperidone
disease MESH pneumoconiosis
drug DRUGBANK Isoniazid
drug DRUGBANK Rifampicin
drug DRUGBANK Pyrazinamide
drug DRUGBANK Ethambutol
disease IDO process
disease MESH causes of death
disease MESH Lung Diseases
disease MESH COVID 19
disease MESH vitamin deficiency
disease IDO contact tracing
disease IDO assay
drug DRUGBANK Meticillin
drug DRUGBANK Vancomycin
disease IDO bacteria
disease MESH extensively drug resistant tuberculosis
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Tretamine

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *